Chronic Kidney Disease, Stage IV (Severe)
5
0
0
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
20.0%
1 terminated out of 5 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
50%
1 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Epidemiology And Risk Factors Of Intradialytic Hypotension In Maintenance Hemodialysis Patients
Living With CKD: An E-Learning Platform for Adolescents With CKD About the Disease and Its Management
MRI Assessment of Myocardial Fibrosis Associated With Monocyte Phenotype in End Stage Renal Failure
Severe Renal Disease Study in Fabry Patients Treated With Fabrazyme
The Study of Immunogenicity of Quadrivalent Vaccine Against Human Papilloma Virus (HPV) Types 6, 11, 16, and 18 (HPV-6/11/16/18) in Chronic Kidney Disease (CKD) Patients